| Abstrakt: |
A patent has been issued to Janssen Biotech Inc. for neoantigens expressed in ovarian cancer and their potential uses in therapies against the disease. Ovarian cancer is a leading cause of cancer-related deaths in women, with a high risk of recurrence and poor survival rates. The patent discloses isolated polypeptides and polynucleotides that could be used in the development of new treatments for ovarian cancer, including cases that are relapsed, refractory, or platinum-resistant. The patent describes various vectors, including adenovirus, poxvirus, adeno-associated virus, retrovirus, and self-replicating RNA molecules, that can be used in the treatment of ovarian cancer. These vectors contain polynucleotides that encode multiple polypeptides, which can be connected to each other in any order. The patent also mentions a pharmaceutical composition comprising the vector. For more detailed information, please refer to the full patent. [Extracted from the article] |
